| Předmět: |
|
| Zdroj: |
Urology Times; Nov2020, Vol. 48 Issue 11, p28-30, 3p |
| Abstrakt: |
The article discusses the results of the CARD study on the use of cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and looks at the real-world implications of these results. Topics mentioned include the benefits of cabazitaxel treatment in terms of imaging-based progression-free survival (PFS) and overall survival (OS), and the other treatment options for mCRPC including androgen deprivation therapy and chemotherapy with docetaxel. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
